Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.05 -0.00%

-$0.00 today

Market cap
$122.39M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 1.87M

Average 2.92M

FATE Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Fate Therapeutics, Inc.NASDAQ: FATE

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $1.3M fell 20.3% year over year, ahead of the -52.6% change in trailing-twelve-month revenue. Sequentially, it fell 5.1% from the prior quarter. Over 3 fiscal years it compounded at -59.0% a year.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 6 analysts of $5.71M (-14.1%) for the fiscal year ending Dec 2026, a step up from the -51.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.3M-5.1% QoQ
Last fiscal yearDec 2025
$6.65M-51.2% YoY
LTMMar 2026
$6.32M-52.6% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-20.3%-29.7%-9.5 pp
1 year-51.2%-14.1%+37.2 pp
3-year CAGR-59.0%-22.5%+36.5 pp
5-year CAGR+73.8%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
6.65M USD
Year-over-year change
-51.2%
4-year CAGR
-41.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How FATE compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -52.6% is the 2nd highest of 5, against a peer median of -89.6%.
  • Over three fiscal years its annual growth of -59.0% compares with a peer median of -63.7%.
FATE Competitors
Revenue for FATE and competitors
Company Period LTM YoY 3-year CAGR
ALECAlector, Inc.LTM Mar 2026$18.42M USD-79.2%-46.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.72M USD+138.9%—
FATEFate Therapeutics, Inc.LTM Mar 2026$6.32M USD-52.6%-59.0%
VORVor Biopharma Inc.LTM Mar 2026$0 USD——
PEPGPepGen Inc.LTM Mar 2026$0 USD——
MOLNMolecular Partners AGLTM Mar 2026CHF 0 CHF-100.0%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$0 USD-100.0%-81.5%
NKTXNkarta, Inc.LTM Mar 2026$0 USD——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD——
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$0 USD——
Peer median (excluding FATE) —-89.6%-63.7%

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.